Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Iambic Therapeutics IPO Targets $806M Valuation
Nvidia-backed Iambic Therapeutics plans a Nasdaq IPO at $15 to $17 a share, valuing the AI drug discovery firm at up to about $806 million.
FDA Extends Mifepristone Safety Review Into 2027
The FDA told a federal court its mifepristone safety review will run into 2027, with a report due by March. Timeline, context and what changes now.
Argenx Stock Falls After Phase 3 Sjögren’s Trial Stops
Argenx stops its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease for futility; shares fell about 16%. What it means for the pipeline.
India Caps Cancer Drug Trade Margins at 30% of MRP
Will cancer drugs get cheaper? India caps trade margins on non-scheduled cancer medicines at 30% of MRP; some prices may fall up to 70%.
Pennsylvania Measles Outbreak Reaches 1,078 Cases
Pennsylvania reports 1,078 measles cases in 41 counties, 207 hospitalisations and 5 deaths. Here is what the latest update means and who needs MMR.
Supreme Court Orders Panel on Pharma Freebies to Doctors
Supreme Court directs the Centre to form a committee on pharma freebies to doctors in India, as the UCPMP marketing code faces an enforcement test.
Veteran Actor Nana Patekar Dies at 75 in Goa
Veteran actor Nana Patekar died at 75 in Goa on 8 October 2026. What is known about the cardiac emergency, his career and what happens next.
Biohub Virtual Biology Initiative Gets $1.8B AI Backing
Google DeepMind, Meta and the US government back a $1.8B Biohub AI push for virtual cell models. Who pays what and what it means for drug discovery.
Spencer Stiles to Succeed Kevin Lobo as Stryker CEO
Stryker names Spencer Stiles CEO from 1 January 2027 as Kevin Lobo, CEO since 2012, becomes Executive Chair. What it means for robotics and acquisitions.
FDA Approves First Symptomatic Dermographism Treatment
FDA approves Novartis Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism. RemIND Phase III data, safety and what patients should know.